NCT00400374View on ClinicalTrials.gov

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

November 30, 2016

Conditions
Head and Neck Cancer
Interventions
DRUG

Erlotinib

Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.

DRUG

Celecoxib

Celecoxib, 400 mg, daily for 6 months.

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER